Craig Hallum Begins Coverage on Harrow Health (NASDAQ:HROW)

Stock analysts at Craig Hallum assumed coverage on shares of Harrow Health (NASDAQ:HROW - Get Free Report) in a report released on Thursday, MarketBeat.com reports. The brokerage set a "buy" rating and a $24.00 price target on the stock. Craig Hallum's target price would indicate a potential upside of 81.96% from the company's previous close.

Separately, B. Riley reduced their price target on shares of Harrow Health from $30.00 to $26.00 and set a "buy" rating for the company in a report on Friday, March 22nd.

Harrow Health Stock Up 2.0 %

Shares of NASDAQ:HROW traded up $0.26 during trading hours on Thursday, hitting $13.19. The company's stock had a trading volume of 412,325 shares, compared to its average volume of 437,406. Harrow Health has a 52 week low of $7.60 and a 52 week high of $28.25. The company has a debt-to-equity ratio of 2.60, a current ratio of 2.83 and a quick ratio of 2.61. The company has a market capitalization of $466.44 million, a price-to-earnings ratio of -17.59 and a beta of 0.48. The firm's fifty day moving average price is $11.41 and its 200 day moving average price is $11.46.

Harrow Health (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Tuesday, March 19th. The company reported ($0.27) EPS for the quarter. Harrow Health had a negative net margin of 18.75% and a negative return on equity of 29.48%. The business had revenue of $36.36 million during the quarter, compared to the consensus estimate of $37.65 million. As a group, research analysts expect that Harrow Health will post -0.39 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Opaleye Management Inc. acquired 50,600 shares of Harrow Health stock in a transaction that occurred on Wednesday, March 20th. The stock was purchased at an average price of $9.65 per share, for a total transaction of $488,290.00. Following the purchase, the insider now directly owns 3,695,600 shares in the company, valued at approximately $35,662,540. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder Opaleye Management Inc. purchased 50,600 shares of the business's stock in a transaction on Wednesday, March 20th. The shares were acquired at an average price of $9.65 per share, for a total transaction of $488,290.00. Following the purchase, the insider now owns 3,695,600 shares of the company's stock, valued at approximately $35,662,540. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mark L. Baum purchased 9,000 shares of the business's stock in a transaction on Friday, March 22nd. The shares were bought at an average price of $11.59 per share, for a total transaction of $104,310.00. Following the purchase, the chief executive officer now directly owns 2,137,525 shares in the company, valued at approximately $24,773,914.75. The disclosure for this purchase can be found here. Insiders bought a total of 109,600 shares of company stock worth $1,233,600 in the last 90 days. 13.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HROW. Marshall Wace LLP boosted its holdings in shares of Harrow Health by 4.0% in the 3rd quarter. Marshall Wace LLP now owns 26,999 shares of the company's stock valued at $326,000 after acquiring an additional 1,030 shares during the last quarter. UBS Group AG boosted its holdings in shares of Harrow Health by 11.2% in the 4th quarter. UBS Group AG now owns 12,718 shares of the company's stock valued at $188,000 after acquiring an additional 1,279 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Harrow Health by 10.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,639 shares of the company's stock valued at $176,000 after acquiring an additional 1,523 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Harrow Health by 2.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 81,829 shares of the company's stock valued at $916,000 after acquiring an additional 1,697 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Harrow Health in the 3rd quarter valued at $26,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Health Company Profile

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.